Johnson & Johnson: Familial Primary Pulmonary Hypertension trials

The registry lists 35 Familial Primary Pulmonary Hypertension studies with Johnson & Johnson as lead sponsor. 0 are open to participants now and 24 have results posted.

Phase 2 2Phase 3 19Phase 4 11No phase 3(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Study of Selexipag Assessing Right Ventricular Remodeling in Pulmonary Arterial Hypertension by Cardiac Magnetic Resonance ImagingTerminatedNCT04435782Phase 4Results posted
• Effect of Selexipag on Daily Life Physical Activity of Patients With Pulmonary Arterial Hypertension.CompletedNCT03078907Phase 4Results posted
• The Efficacy and Safety of Initial Triple Versus Initial Dual Oral Combination Therapy in Patients With Newly Diagnosed Pulmonary Arterial HypertensionCompletedNCT02558231Phase 3Results posted
• Study to Assess the Tolerability and the Safety of the Transition From Inhaled Treprostinil to Oral Selexipag in Patients With Pulmonary Arterial HypertensionCompletedNCT02471183Phase 3Results posted
• REPAIR: Right vEntricular Remodeling in Pulmonary ArterIal hypeRtensionCompletedNCT02310672Phase 4Results posted
• A Pulmonary Arterial Hypertension Study With Macitentan to Validate the PAH-SYMPACT™ in France, Italy and SpainTerminatedNCT02081690Phase 3Results posted
• Clinical Study of Macitentan in Patients With PAH to Psychometrically Validate PAH-SYMPACT InstrumentTerminatedNCT01847014Phase 3Results posted
• Clinical Study of Macitentan in Patients With Pulmonary Arterial Hypertension to Psychometrically Validate the PAH-SYMPACT InstrumentCompletedNCT01841762Phase 3Results posted
• Epoprostenol for Injection in Patients With Pulmonary Arterial HypertensionCompletedNCT01470144Phase 3Results posted
• Epoprostenol for Injection (EFI/ACT-385781A) - Pulmonary Arterial HypertensionCompletedNCT01431716Phase 3Results posted
• FUTURE 3 Study ExtensionCompletedNCT01338415Phase 3Results posted
• Effects of Two Dosing Regimens of Bosentan in Children With Pulmonary Arterial HypertensionCompletedNCT01223352Phase 3Results posted
• ACT-293987 in Pulmonary Arterial HypertensionCompletedNCT01112306Phase 3Results posted
• Epoprostenol for Injection in Pulmonary Arterial Hypertension - Extension of AC-066A401CompletedNCT01105117Phase 4Results posted
• Epoprostenol for Injection in Pulmonary Arterial HypertensionCompletedNCT01105091Phase 4Results posted
• Iloprost Power Disc-15 in Pulmonary Arterial HypertensionTerminatedNCT00723554Phase 3Results posted
• Iloprost Power 15 in Pulmonary Arterial HypertensionCompletedNCT00709956Phase 3Results posted
• Safety Study Extension of Iloprost Power 15 in Pulmonary Arterial HypertensionCompletedNCT00709098Phase 3Results posted
• Clinical Study to Assess the Long-term Safety and Tolerability of ACT 064992 in Patients With Symptomatic Pulmonary Arterial HypertensionCompletedNCT00667823Phase 3Results posted
• Study of Macitentan (ACT-064992) on Morbidity and Mortality in Patients With Symptomatic Pulmonary Arterial HypertensionCompletedNCT00660179Phase 3Results posted
• Combination Therapy in Pulmonary Arterial HypertensionCompletedNCT00433329Phase 4Results posted
• BREATHE 5-OL: Tracleer (Bosentan) in Patients With Pulmonary Arterial Hypertension Related to Eisenmenger PhysiologyCompletedNCT00367770Phase 4Results posted
• Bosentan in Children With Pulmonary Arterial Hypertension Extension StudyCompletedNCT00319020Phase 3Results posted
• Effects of the Combination of Bosentan and Sildenafil Versus Sildenafil Monotherapy on Pulmonary Arterial Hypertension (PAH)CompletedNCT00303459Phase 4Results posted
• A Study of Real-world Cohort of Pulmonary Arterial Hypertension (PAH) ParticipantsTerminatedNCT04955990Phase 4
• A Clinical Study to Investigate the Long-term Safety of the Drug Macitentan in Patients With Pulmonary Hypertension Who Were Previously Treated With Macitentan in Clinical Studies.CompletedNCT03422328Phase 3
• Clinical Study Evaluating the Effects of First-line Oral cOmbination theraPy of maciTentan and tadalafIl in Patients With Newly Diagnosed pulMonary Arterial Hypertension (OPTIMA)TerminatedNCT02968901Phase 4
• Correlation of LONGterm Wrist ACTigraphy Recorded Physical Performance & 6-minute Walk Distance in Patients With Pulmonary Arterial HypertensionWithdrawnNCT02309463
• Extension of the Psychometric Validation Study ORCHESTRA in Patients With PAHCompletedNCT02112487Phase 3
• Ventavis® Registry ProtocolTerminatedNCT00902603
• Early, Simple and Reliable Detection of Pulmonary Arterial Hypertension (PAH) in Systemic Sclerosis (SSc)TerminatedNCT00706082
• Safety and Efficacy of Inhaled Iloprost in Pediatric Patients With Pulmonary Arterial HypertensionWithdrawnNCT00453414Phase 2
• Bosentan in Children With Pulmonary Arterial HypertensionCompletedNCT00319267Phase 3
• Effects of Tracleer (Bosentan) on Pulmonary Arterial Hypertension Related to Eisenmenger PhysiologyCompletedNCT00317486Phase 4
• Trial of Iloprost Inhaled Solution as Add-On Therapy With Bosentan in Subjects With Pulmonary Arterial Hypertension (PAH)CompletedNCT00086463Phase 2